Literature DB >> 19036103

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.

Carlos M Galmarini, Finn Myhren, Marit L Sandvold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19036103     DOI： 10.1111/j.1365-2141.2008.07467.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

1.  Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

Authors:  Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles
Journal:  Br J Haematol       Date:  2012-06-15       Impact factor: 6.998

2.  The way forward in treating pancreatic cancer.

Authors:  Valeriy Sedov; Elizabeth Poplin
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

Review 3.  Lipid-based drug carriers for prodrugs to enhance drug delivery.

Authors:  Jennica L Zaro
Journal:  AAPS J       Date:  2014-10-01       Impact factor: 4.009

4.  Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Authors:  Francis Giles; David Rizzieri; Farhad Ravandi; Ronan Swords; Tove Flem Jacobsen; Susan O'Brien
Journal:  Leuk Res       Date:  2012-01-09       Impact factor: 3.156

Review 5.  Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Authors:  Lindsay A M Rein; David A Rizzieri
Journal:  Ther Adv Hematol       Date:  2014-12

6.  Antiproliferative and apoptotic activity of gemcitabine-lauric acid conjugate on human bladder cancer cells.

Authors:  Hongxia Wang; Zhiyu Shao; Zhiwen Xu; Binghao Ye; Ming Li; Qiaoqiao Zheng; Xingyuan Ma; Ping Shi
Journal:  Iran J Basic Med Sci       Date:  2022-04       Impact factor: 2.532

7.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Authors:  Andries M Bergman; Auke D Adema; Jan Balzarini; Skjalg Bruheim; Iduna Fichtner; Paul Noordhuis; Oystein Fodstad; Finn Myhren; Marit L Sandvold; Hans R Hendriks; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2010-01-12       Impact factor: 3.850

Review 8.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 9.  Improving nucleoside analogs via lipid conjugation: Is fatter any better?

Authors:  Peter Alexander; Gregory Kucera; Timothy S Pardee
Journal:  Crit Rev Oncol Hematol       Date:  2016-01-21       Impact factor: 6.312

10.  Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.

Authors:  Auke D Adema; Kees Smid; Nienke Losekoot; Richard J Honeywell; Henk M Verheul; Finn Myhren; Marit L Sandvold; Godefridus J Peters
Journal:  Invest New Drugs       Date:  2011-10-15       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.